Cyclo Therapeutics Stock Current Liabilities
CYTH Stock | USD 0.66 0.02 2.94% |
Cyclo Therapeutics fundamentals help investors to digest information that contributes to Cyclo Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyclo Stock. The fundamental analysis module provides a way to measure Cyclo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclo Therapeutics stock.
The Cyclo Therapeutics' current Total Current Liabilities is estimated to increase to about 8.9 M, while Non Current Liabilities Total is projected to decrease to under 21.4 K. Cyclo | Current Liabilities |
Cyclo Therapeutics Company Current Liabilities Analysis
Cyclo Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Cyclo Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Cyclo Therapeutics is extremely important. It helps to project a fair market value of Cyclo Stock properly, considering its historical fundamentals such as Current Liabilities. Since Cyclo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cyclo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cyclo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cyclo Current Liabilities Historical Pattern
Today, most investors in Cyclo Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cyclo Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cyclo Therapeutics current liabilities as a starting point in their analysis.
Cyclo Therapeutics Current Liabilities |
Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition |
Cyclo Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Cyclo Therapeutics has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
All Next | Launch Module |
Cyclo Fundamentals
Return On Equity | -226.64 | ||||
Return On Asset | -2.82 | ||||
Operating Margin | (45.78) % | ||||
Current Valuation | 30.84 M | ||||
Shares Outstanding | 28.77 M | ||||
Shares Owned By Insiders | 40.07 % | ||||
Shares Owned By Institutions | 13.17 % | ||||
Number Of Shares Shorted | 131.61 K | ||||
Price To Book | 59.10 X | ||||
Price To Sales | 17.27 X | ||||
Revenue | 1.08 M | ||||
Gross Profit | 1.23 M | ||||
EBITDA | (20.03 M) | ||||
Net Income | (20.06 M) | ||||
Cash And Equivalents | 4.29 M | ||||
Cash Per Share | 0.51 X | ||||
Total Debt | 1.03 M | ||||
Current Ratio | 2.93 X | ||||
Book Value Per Share | 0.17 X | ||||
Cash Flow From Operations | (16.19 M) | ||||
Short Ratio | 3.82 X | ||||
Earnings Per Share | (0.90) X | ||||
Target Price | 0.95 | ||||
Beta | -0.38 | ||||
Market Capitalization | 19.56 M | ||||
Total Asset | 13.25 M | ||||
Retained Earnings | (83.86 M) | ||||
Working Capital | 3.85 M | ||||
Net Asset | 13.25 M |
About Cyclo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyclo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:Check out Cyclo Therapeutics Piotroski F Score and Cyclo Therapeutics Altman Z Score analysis. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.